What is pathophysiology of Lung cancer?

Gee ntị na peeji a

Gịnị bụ pathophysiology nke ọrịa cancer akpa ume?

Pathophysiology nke ọrịa cancer akpa ume na-ezo aka na mgbanwe na usoro na usoro physiological nkịtị nke na-eme na mmepe na ọganihu nke ọrịa cancer akpa ume.

Ọrịa cancer akpa ume bụ ọrịa dị mgbagwoju anya nke na- esi n" uto na nkewa nke mkpụrụ ndụ ndị na- adịghị mma n" akpa ume apụta .

Mkpụrụ ndụ ndị a pụrụ imepụta akwara ma gbasaa n'akụkụ ndị ọzọ nke ahụ, na-eduga n'ihe mgbaàmà na nsogbu dị iche iche.

Pathophysiology nke ọrịa cancer akpa ume na-agụnye ọtụtụ ihe, gụnyere mgbanwe mkpụrụ ndụ ihe nketa, ihe ndị na-eme gburugburu ebe obibi, na nhọrọ ndụ.

Mgbanwe mkpụrụ ndụ ihe nketa pụrụ ime na DNA nke mkpụrụ ndụ akpa ume, na-eduga n'uto na nkewa nke mkpụrụ ndụ n'enweghị nchịkwa.

Mgbanwe ndị a pụrụ ịbụ nke a ketara eketa ma ọ bụ nke a nwetara, ha pụkwara ịbụ nke ihe ndị na-akpata ọrịa cancer, dị ka anwụrụ ọkụ ụtaba, radon, asbestos, na mmetọ ikuku na-akpata.

A pụrụ ikewapụ ọrịa cancer akpa ume n'ụdị abụọ: obere ọrịa cancer akpa ume (SCLC) na ọrịa cancer akpa ume na-abụghị obere ọrịa cancer (NSCLC). A na-ekewa NSCLC n'ụdị atọ: adenocarcinoma, squamous cell carcinoma, na large cell carcinoma.

Pathophysiology nke ụdị ọrịa cancer akpa ume ndị a nwere ike ịdị iche, ebe ọ bụ na ha nwere mgbanwe mkpụrụ ndụ ihe nketa dị iche iche ma zaghachi ọgwụgwọ n'ụzọ dị iche.

Pathophysiology nke ọrịa cancer akpa ume na-agụnyekwa mmekọrịta dị n'etiti mkpụrụ ndụ kansa na anụ ahụ gbara ya gburugburu, gụnyere usoro ahụ ji alụso ọrịa ọgụ.

Mkpụrụ ndụ kansa pụrụ ịgbanahụ usoro ahụ ji alụso ọrịa ọgụ, na-ekwe ka ha too ma na-agbasa n'enweghị ihe mgbochi.

Tụkwasị na nke ahụ, microenvironment nke akpụ ahụ nwere ike ịkwalite uto akpụ na metastasis site n'inye gburugburu ebe obibi na-akwado mkpụrụ ndụ kansa.

Pathophysiology nke ọrịa cancer akpa ume bụ usoro dị mgbagwoju anya na nke na-agbanwe agbanwe, ndị nchọpụta na-arụkwa ọrụ mgbe nile iji ghọtakwuo usoro ndị dị n'okpuru ya iji zụlite ọgwụgwọ ndị dị irè karị ma melite nsonaazụ ndị ọrịa.

Ihe ndị e dere na ya

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.

Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.

Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.

Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .

Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .

Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.

Nkwupụta: ọgwụgwọ

A na-enye weebụsaịtị a maka ebumnuche agụmakwụkwọ na ozi naanị ma ọ bụghị inye ndụmọdụ ahụike ma ọ bụ ọrụ ọkachamara.

E kwesịghị iji ihe ọmụma e nyere mee ihe maka ịchọpụta ma ọ bụ ịgwọ nsogbu ahụ ike ma ọ bụ ọrịa, ndị na-achọ ndụmọdụ ahụike onwe ha kwesịrị ịgakwuru dọkịta nwere ikike.

Biko rịba ama na netwọkụ akwara nke na-emepụta azịza nye ajụjụ ndị ahụ, bụ ihe na-ezighi ezi mgbe ọ na-abịa na ọnụọgụ ọnụọgụ. Dịka ọmụmaatụ, ọnụọgụ ndị mmadụ chọpụtara na ọrịa akọwapụtara.

Na-achọkarị ndụmọdụ nke dọkịta gị ma ọ bụ onye na-ahụ maka ahụike ọzọ ruru eru banyere ọnọdụ ahụike. Elegharala ndụmọdụ ahụike ọkachamara anya ma ọ bụ na-egbu oge n'ịchọ ya n'ihi ihe ị gụrụ na weebụsaịtị a. Ọ bụrụ na i chere na ị nwere ike ịnweta mberede ahụike, kpọọ 911 ma ọ bụ gaa n'ọnụ ụlọ mberede kacha nso ozugbo. Enweghị mmekọrịta dọkịta na onye ọrịa na-emepụta site na weebụsaịtị a ma ọ bụ ojiji ya. Ma BioMedLib ma ndị ọrụ ya, ma onye ọ bụla na-enye aka na weebụsaịtị a, anaghị eme nkwupụta ọ bụla, kwupụta ma ọ bụ kwupụta, gbasara ozi enyere ebe a ma ọ bụ ojiji ya.

Nkwupụta: ikike nwebisiinka

Digital Millennium Copyright Act nke 1998, 17 U.S.C. § 512 (DMCA) na-enye ohere maka ndị nwe ikike nwebisiinka nke kwenyere na ihe na-apụta na ịntanetị na-emebi ikike ha n'okpuru iwu ikike nwebisiinka US.

Ọ bụrụ na ị kwenyere n'ezi okwukwe na ọdịnaya ma ọ bụ ihe ọ bụla enyere na njikọ nke weebụsaịtị anyị ma ọ bụ ọrụ na-emebi ikike nwebisiinka gị, gị (ma ọ bụ onye nnọchi anya gị) nwere ike iziga anyị ọkwa na-arịọ ka ewepụ ọdịnaya ma ọ bụ ihe, ma ọ bụ gbochie ịnweta ya.

A ghaghị izipu ọkwa n'akwụkwọ site na email (lee ngalaba "Kọntaktị" maka adreesị email) .

DMCA na-achọ ka ọkwa gị banyere mmebi iwu nwebisiinka na-ekwu na ọ gụnyere ozi ndị a: (1) nkọwa nke ọrụ nwebisiinka nke bụ isiokwu nke mmebi iwu a na-ekwu; (2) nkọwa nke ihe a na-ekwu na ọ na-emebi iwu na ozi zuru ezu iji mee ka anyị chọta ọdịnaya ahụ; (3) ozi kọntaktị maka gị, gụnyere adreesị gị, nọmba ekwentị na adreesị email; (4) nkwupụta site n'aka gị na ị nwere ezi okwukwe na ọdịnaya n'ụzọ a na-eme mkpesa na ọ bụghị ikike site n'aka onye nwe ikike, ma ọ bụ onye nnọchi anya ya, ma ọ bụ site na ọrụ iwu ọ bụla;

(5) nkwupụta site n'aka gị, nke ị bịanyere aka na ya n'okpuru ntaramahụhụ nke ịgba akaebe ụgha, na ozi dị na ọkwa ahụ ziri ezi na na ị nwere ikike iji mezuo ikike nwebisiinka nke a na-ekwu na emebi;

na (6) mbinye aka nkịtị ma ọ bụ nke elektrọnik nke onye nwe ikike ma ọ bụ onye e nyere ikike ime ihe n'aha onye nwe ikike.

Ọ bụrụ na i tinyeghị ozi niile dị n'elu, ọ nwere ike ime ka a na-egbu oge n'ịhazi mkpesa gị.

Mkparịta ụka

Biko zitere anyị email na ajụjụ ọ bụla / aro.

What is pathophysiology of lung cancer?

The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.

Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.

These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.

The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.

Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.

These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.

Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.

The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.

Cancer cells can evade the immune system, allowing them to grow and spread unchecked.

Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.

The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.